A Phase 3 interventional study of peginterferon alfa-2b (SCH 54031) in Chronic Hepatitis C and Liver Fibrosis, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-04-04.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C, Chronic.
Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, this one is the 6th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2002, is one of 22 in phase 3, and was the 2nd registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 4 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 540 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 99 across the 39 interventional studies. Of the 35 that completed or were terminated, 21 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 40 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
110 studies in Hepatitis C, Chronic by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 106 finished, 81 (76%) have results posted.
Among the 110 studies in Hepatitis C, Chronic by Merck & Co., Inc, this one is the 11th largest by enrollment of the 72 interventional ones that give a count, is one of 3 that started in 2002, is one of 32 in phase 3, and was the 3rd registered.
Merck & Co., Inc’s Hepatitis C, Chronic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 110 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of the study is to evaluate the safety and efficacy of PEG-Intron versus no treatment for the prevention of fibrosis progression in adult participants with moderate to severe liver fibrosis secondary to chronic hepatitis C, who failed PEG-Intron plus Rebetol treatment in protocol P02370 (NCT00039871).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PEG-Intron 0.5 µg/kg Weekly (QW) subcutaneously (SC) as maintenance therapy for 36 months with 4-week follow-up
Biological: peginterferon alfa-2b (SCH 54031)
0.5 µg/kg Weekly QW SC for 36 months
Fibrosis Response Status (ie, Improvement, no Change, or the Worsening of the Fibrosis Score in Participants With Baseline METAVIR Fibrosis Score of F2 or F3).
Definitions: Fibrosis scoring: F0 (no fibrosis), F1 (stellate enlargement of portal tract without septa formation, F2 (enlargement of portal tract with rare septa formation, F3 (numerous septa without cirrhosis), F4 (cirrhosis). Improved: Participants whose METAVIR fibrosis score at up to Month-36 decreases by 1 or more units compared to baseline. No Change: Participants whose METAVIR fibrosis score at up to Month-36 is the same as the baseline score. Worsened: Participants whose METAVIR fibrosis score at up to Month-36 increases by 1 or more units compared to baseline.
Time frame: Baseline to up to Month-36
Inflammation Response Status (ie, Improvement, no Change, or the Worsening of the METAVIR Activity Score as Compared to Baseline)
Activity Scoring: A0 (no histological activity), A1 (minimal activity), A2 (moderate activity), A3 (severe activity), A4 (lobular chronic hepatitis). Changes in liver inflammation defined as follows: Improved: Participants whose METAVIR activity score at up to Month-36 decreases by 1 or more units compared to baseline. No Change: Participants whose METAVIR activity score at up to Month-36 is the same as the baseline score. Worsened: Participants whose METAVIR activity score at up to Month-36 increases by 1 or more units compared to baseline.
Time frame: Baseline to up to Month-36
Mean Change From Baseline to up to Month-36 in the METAVIR Fibrosis Score (Using a Continuous Scale)
The change of Metavir Fibrosis Score = Metavir Fibrosis Score at up to Month-36 - Metavir Fibrosis Score at Baseline. Fibrosis scoring: 0 (no fibrosis), 1 (stellate enlargement of portal tract without septa formation, 2 (enlargement of portal tract with rare septa formation, 3 (numerous septa without cirrhosis), 4 (cirrhosis).
Time frame: Baseline to up to Month-36
The Number of Participants Whose METAVIR Fibrosis Score Did Not Worsen (ie, the Response Status of Improved/no Change) During Treatment Compared to Baseline
Definitions: Fibrosis scoring: F0 (no fibrosis), F1 (stellate enlargement of portal tract without septa formation, F2 (enlargement of portal tract with rare septa formation, F3 (numerous septa without cirrhosis), F4 (cirrhosis). Improved: Participants whose METAVIR fibrosis score at up to Month-36 decreases by 1 or more units compared to baseline. No Change: Participants whose METAVIR fibrosis score at up to Month-36 is the same as the baseline score. Worsened: Participants whose METAVIR fibrosis score at up to Month-36 increases by 1 or more units compared to baseline.
Time frame: Baseline to up to Month-36
Mean Change in the METAVIR Activity Score (Using a Continuous Scale)
The change of Metavir Activity Score = Metavir Activity Score at up to Month-36 - Metavir Activity Score at Baseline. Activity Scoring: 0 (no histological activity), 1 (minimal activity), 2 (moderate activity), 3 (severe activity), 4 (lobular chronic hepatitis).
Time frame: Baseline to up to Month-36
Number of Participants With no Worsening (ie, the Response Status of Improved/ no Change) in the METAVIR Activity Score During the Treatment.
Definitions: Activity Scoring: A0 (no histological activity), A1 (minimal activity), A2 (moderate activity), A3 (severe activity), A4 (lobular chronic hepatitis). Improved: Participants whose METAVIR activity score at up to Month-36 decreases by 1 or more units compared to baseline. No Change: Participants whose METAVIR activity score at up to Month-36 is the same as the baseline score. Worsened: Participants whose METAVIR activity score at up to Month-36 increases by 1 or more units compared to baseline.
Time frame: Baseline to up to Month-36
| Milestone | PEG-Intron (Peginterferon Alfa-2b) 0.5 µg/kg Weekly (QW) | Untreated Control |
|---|---|---|
| Started | 270 | 270 |
| Completed | 177 | 192 |
| Not completed | 93 | 78 |
| Withdrew: Adverse event | 47 | 12 |
| Withdrew: Withdrawal by subject | 35 | 46 |
| Withdrew: Non-compliance with protocol | 7 | 8 |
| Withdrew: Lost to follow-up | 4 | 8 |
| Withdrew: Administrative | 0 | 3 |
| Withdrew: Did not meet protocol eligibility | 0 | 1 |
| Milestone | PEG-Intron (Peginterferon Alfa-2b) 0.5 µg/kg Weekly (QW) | Untreated Control |
|---|---|---|
| Started | 218 | 194 |
| Completed | 211 | 189 |
| Not completed | 7 | 5 |
| Withdrew: Adverse event | 6 | 1 |
| Withdrew: Other | 1 | 4 |
Definitions: Fibrosis scoring: F0 (no fibrosis), F1 (stellate enlargement of portal tract without septa formation, F2 (enlargement of portal tract with rare septa formation, F3 (numerous septa without cirrhosis), F4 (cirrhosis). Improved: Participants whose METAVIR fibrosis score at up to Month-36 decreases by 1 or more units compared to baseline. No Change: Participants whose METAVIR fibrosis score at up to Month-36 is the same as the baseline score. Worsened: Participants whose METAVIR fibrosis score at up to Month-36 increases by 1 or more units compared to baseline.
| Participants | PEG-Intron (Peginterferon Alfa-2b) 0.5 µg/kg Weekly (QW) | Untreated Control |
|---|---|---|
| Improved | 44 | 29 |
| No Change | 162 | 176 |
| Worsened | 64 | 65 |
Activity Scoring: A0 (no histological activity), A1 (minimal activity), A2 (moderate activity), A3 (severe activity), A4 (lobular chronic hepatitis). Changes in liver inflammation defined as follows: Improved: Participants whose METAVIR activity score at up to Month-36 decreases by 1 or more units compared to baseline. No Change: Participants whose METAVIR activity score at up to Month-36 is the same as the baseline score. Worsened: Participants whose METAVIR activity score at up to Month-36 increases by 1 or more units compared to baseline.
| Participants | PEG-Intron (Peginterferon Alfa-2b) 0.5 µg/kg Weekly (QW) | Untreated Control |
|---|---|---|
| Improved | 54 | 23 |
| No Change | 195 | 209 |
| Worsened | 21 | 38 |
The change of Metavir Fibrosis Score = Metavir Fibrosis Score at up to Month-36 - Metavir Fibrosis Score at Baseline. Fibrosis scoring: 0 (no fibrosis), 1 (stellate enlargement of portal tract without septa formation, 2 (enlargement of portal tract with rare septa formation, 3 (numerous septa without cirrhosis), 4 (cirrhosis).
| Units on a scale | PEG-Intron (Peginterferon Alfa-2b) 0.5 µg/kg Weekly (QW) | Untreated Control |
|---|---|---|
| Mean Change From Baseline to up to Month-36 in the METAVIR Fibrosis Score (Using a Continuous Scale) | 0.13 ± 0.977 | 0.31 ± 1.002 |
Definitions: Fibrosis scoring: F0 (no fibrosis), F1 (stellate enlargement of portal tract without septa formation, F2 (enlargement of portal tract with rare septa formation, F3 (numerous septa without cirrhosis), F4 (cirrhosis). Improved: Participants whose METAVIR fibrosis score at up to Month-36 decreases by 1 or more units compared to baseline. No Change: Participants whose METAVIR fibrosis score at up to Month-36 is the same as the baseline score. Worsened: Participants whose METAVIR fibrosis score at up to Month-36 increases by 1 or more units compared to baseline.
| Participants | PEG-Intron (Peginterferon Alfa-2b) 0.5 µg/kg Weekly (QW) | Untreated Control |
|---|---|---|
| Improved/No Change | 206 | 205 |
| Worsened | 64 | 65 |
The change of Metavir Activity Score = Metavir Activity Score at up to Month-36 - Metavir Activity Score at Baseline. Activity Scoring: 0 (no histological activity), 1 (minimal activity), 2 (moderate activity), 3 (severe activity), 4 (lobular chronic hepatitis).
| Units on a scale | PEG-Intron (Peginterferon Alfa-2b) 0.5 µg/kg Weekly (QW) | Untreated Control |
|---|---|---|
| Mean Change in the METAVIR Activity Score (Using a Continuous Scale) | -0.20 ± 0.709 | 0.11 ± 0.642 |
Definitions: Activity Scoring: A0 (no histological activity), A1 (minimal activity), A2 (moderate activity), A3 (severe activity), A4 (lobular chronic hepatitis). Improved: Participants whose METAVIR activity score at up to Month-36 decreases by 1 or more units compared to baseline. No Change: Participants whose METAVIR activity score at up to Month-36 is the same as the baseline score. Worsened: Participants whose METAVIR activity score at up to Month-36 increases by 1 or more units compared to baseline.
| Participants | PEG-Intron (Peginterferon Alfa-2b) 0.5 µg/kg Weekly (QW) | Untreated Control |
|---|---|---|
| Improved/No Change | 249 | 232 |
| Worsened | 21 | 38 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PEG-Intron | — | 53/270 (19.6%) | 234/270 (86.7%) |
| Untreated Control | — | 31/270 (11.5%) | 200/270 (74.1%) |
| Event | PEG-Intron | Untreated Control |
|---|---|---|
| CHEST PAINGeneral disorders | 3/270 | 1/270 |
| DEPRESSIONPsychiatric disorders | 1/270 | 3/270 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 2/270 | 0/270 |
| DEAFNESS UNILATERALEar and labyrinth disorders | 0/270 | 2/270 |
| RECTAL HAEMORRHAGEGastrointestinal disorders | 2/270 | 0/270 |
| CHOLELITHIASISHepatobiliary disorders | 0/270 | 2/270 |
| LIVER DISORDERHepatobiliary disorders | 2/270 | 0/270 |
| APPENDICITISInfections and infestations | 2/270 | 1/270 |
| PULMONARY TUBERCULOSISInfections and infestations | 2/270 | 0/270 |
| FALLInjury, poisoning and procedural complications | 2/270 | 0/270 |
| Event | PEG-Intron | Untreated Control |
|---|---|---|
| HEADACHENervous system disorders | 76/270 | 24/270 |
| FATIGUEGeneral disorders | 66/270 | 59/270 |
| INSOMNIAPsychiatric disorders | 56/270 | 46/270 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 50/270 | 40/270 |
| ASTHENIAGeneral disorders | 46/270 | 30/270 |
| MYALGIAMusculoskeletal and connective tissue disorders | 46/270 | 20/270 |
| ALOPECIASkin and subcutaneous tissue disorders | 38/270 | 21/270 |
| PRURITUSSkin and subcutaneous tissue disorders | 36/270 | 16/270 |
| INFLUENZA LIKE ILLNESSGeneral disorders | 34/270 | 4/270 |
| DEPRESSIONPsychiatric disorders | 33/270 | 24/270 |
| Age, Customized(participants) | PEG-Intron (Peginterferon Alfa-2b) 0.5 µg/kg Weekly (QW) | Untreated Control | Total |
|---|---|---|---|
| <=50 years | 145 | 148 | 293 |
| >50 years | 125 | 122 | 247 |
| Sex: Female, Male(Participants) | PEG-Intron (Peginterferon Alfa-2b) 0.5 µg/kg Weekly (QW) | Untreated Control | Total |
|---|---|---|---|
| Female | 76 | 81 | 157 |
| Male | 194 | 189 | 383 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
The record gives a start of Oct 2002, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2b